Since its founding in 1995, The Ritedose Corporation has evolved from a small-scale operation into one of the world’s leading specialists in Blow-Fill-Seal (BFS) technology, a platform increasingly recognized for its role in the future of sterile drug manufacturing.
Originally focused on contract manufacturing of sterile, single-dose packaging, Ritedose today leverages BFS to deliver innovation in drug delivery while maintaining a strict commitment to quality and regulatory excellence.
At its core, BFS integrates the forming, filling, and sealing of plastic containers into a fully automated, closed, aseptic process. By eliminating many of the risks inherent to traditional vial filling, BFS has become a preferred solution for ophthalmic products, inhaled medicines, injectable drugs, and other sensitive formulations. For biopharma developers, the technology offers both sterility assurance and patient convenience, two increasingly critical demands as the industry advances toward more complex therapies.
Ritedose’s culture reflects a patient-first philosophy, something CEO Jody Chastain underscores as central to the company’s mission. Throughout its Columbia, S.C. headquarters, photographs of patients serve as reminders that innovation is ultimately measured by its impact on those who depend on these therapies….
Click here to read more about Ritedose’s capabilities and its growth in the Columbia area.
